Results 221 to 230 of about 12,197,984 (249)

Long-Acting Growth Hormone in the Treatment of Children With Growth Hormone Deficiency

open access: yesExpert Review of Endocrinology and Metabolism
The introduction of long-acting formulations in recent years is changing the landscape of growth hormone (GH) therapy. Daily recombinant human GH (rhGH) has been the treatment of choice for children and adults with GH deficiency (GHD), since its approval in 1985. However, decreasing adherence to treatment over time has been identified as a cause of the
Barbara Predieri   +2 more
exaly   +5 more sources

Status of Long-Acting-Growth Hormone Preparations — 2015

Growth Hormone and IGF Research, 2015
Growth hormone (GH) treatment has been an established therapy for GH deficiency (GHD) in children and adults for more than three decades. Numerous studies have shown that GH treatment improves height, body composition, bone density, cardiovascular risk factors, physical fitness and quality of life and that the treatment has few side effects.
Charlotte Höybye   +2 more
exaly   +4 more sources

Long-Acting Growth Hormone Preparations

Endocrinology and Metabolism Clinics of North America
Once-weekly long-acting growth hormone (LAGH) preparations have demonstrated noninferiority compared to daily recombinant human growth hormone in terms of increased growth velocity and improved body composition with comparable short-term safety profiles in children with growth hormone deficiency (CGHD) and adults with growth hormone deficiency (AGHD ...
Margaret Cristina da Silva Boguszewski
exaly   +3 more sources

Long-Acting Growth Hormone Therapy: A REAL3 Alternative to Daily Growth Hormone Treatment?

open access: yesJournal of Clinical Endocrinology and Metabolism, 2020
Michael E. Levine   +2 more
exaly   +3 more sources

Somapacitan: a long-acting growth hormone derivative for treatment of growth hormone deficiency

Drugs of Today, 2022
Growth hormone deficiency (GHD) is characterized by inadequate HG production from the anterior pituitary gland. Adult patients with GHD have increased fat mass, an abnormal lipid profile, decreased lean body mass and bone mineral density, decreased muscle strength and exercise endurance, and a diminished quality of life.
openaire   +2 more sources

Long-Acting Growth Hormone: An Update

2015
After the introduction of recombinant human growth hormone (rhGH) in 1985, a myriad of children and adults have benefited from its growth-promoting and metabolic effects. Nowadays, current therapeutic regimens rely on daily subcutaneous GH injections that could be burdensome and inconvenient to pediatric patients.
Paul H, Saenger, Jorge, Mejia-Corletto
openaire   +2 more sources

Long-Acting Forms of Growth Hormone-Releasing Hormone and Growth Hormone: Effects in Normal Volunteers and Adults With Growth Hormone Deficiency

Hormone Research, 2007
<i>Background:</i> Growth hormone (GH) replacement therapy in adults and children has found broad acceptance by endocrinologists and patients, but the need for daily injections remains a significant barrier to more widespread use. <i>Long-acting Formulations:</i> Several approaches have been taken to develop long-acting forms of
David Clemmons
exaly   +3 more sources

Long-Acting Growth Hormone Analogues

2011
Growth hormone (GH) is an anabolic cytokine hormone regulating linear growth in childhood and normal body composition in adults. The current therapeutic regimen for GH replacement requires once-daily subcutaneous injections which is inconvenient and expensive.
Alice Thorpe   +4 more
openaire   +1 more source

Long-acting growth hormone in the management of GHD in France

Archives de Pédiatrie
Approximately 10,000 children in France with growth hormone deficiency (GHD) are being administered daily recombinant human growth hormone (rhGH). Although this treatment has long proved efficient for restoring children's growth and metabolism, daily injections of rhGH have a few limitations, such as difficulties in terms of adherence to treatment ...
Agnès Linglart   +3 more
openaire   +2 more sources

Novel Long-Acting Crystal Formulation of Human Growth Hormone

Pharmaceutical Research, 2005
The aim of the study is to solve a significant challenge of extending the half-life of therapeutic proteins using crystalline biopharmaceuticals and without redesigning the molecules.Crystals of recombinant human growth hormone were coated with a monomolecular layer of positively charged poly(arginine). The pharmacokinetics and pharmacodynamics of this
Chandrika, Govardhan   +9 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy